- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 25, Issue 1, 2019
Current Pharmaceutical Design - Volume 25, Issue 1, 2019
Volume 25, Issue 1, 2019
-
-
Are Drugs Always the Proper Solution to Therapeutic Dilemmas? Non-drug Approaches to the Post-traumatic Stress “Waking Corpse” Syndrome
Jules Cotard (1840-1889), a Parisian neurologist, described a syndrome of delirium negations which was later named after him. Some physicians in antiquity and medieval times, especially in Asia, have noticed this syndrome and categorized it as a symptom of melancholy. They have presented it as a "walking corpse syndrome", inflicting most probably veteran soldiers after suffering during ferocious battles, presenting the first cas Read More
-
-
-
Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
Introduction: Biosimilars present a considerable potential to reduce costs related to clinical management allowing health-care providers to reinvest this money, leading to a wider access to an effective biological treatment with monoclonal antibodies (mAb). Infliximab biosimilars have already been incorporated in daily clinical practice and are currently used in all indications for which the reference product (RP) was approved. Read More
-
-
-
Biosimilars in IBD: Will it Benefit to Patients, Physicians or the Health Care System?
Authors: Lorant Gonczi, Akos Ilias, Zsuzsanna Kurti and Peter L. LakatosThe introduction of biological drugs has revolutionized the management of inflammatory bowel diseases (IBD), however, the increasing financial burden of biologicals on the health care system is alarming. Biosimilars are considered to be equivalent to the reference medicinal product (RMP) in terms of pharmacokinetic properties, clinical effectiveness and safety. CT-P13 infliximab was the first biosimilar to be approved by the re Read More
-
-
-
Anti-adhesion Molecules in IBD: Does Gut Selectivity Really Make the Difference?
Authors: Ferdinando D'Amico, Giulia Roda, Laurent Peyrin-Biroulet and Silvio DaneseInflammatory Bowel Disease is lifetime chronic progressive inflammatory disease. A considerable portion of patients, do not respond or lose response or experience side effect to “traditional” biological treatment such as anti-tumor necrosis factor (TNF)-α agents. The concept that the blockade of T cell traffic to the gut controls inflammation has stimulated the development of new drugs which selectively targets molecu Read More
-
-
-
Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?
Over the past decades, the advent of anti-TNF agents has dramatically changed the treatment algorithms for IBD. However, primarily and more importantly, secondary loss of response to anti-TNF agents, is often observed. Thus, new treatment options have been actively explored and some have already been incorporated in the current clinical practice. Among the class of anti-cytokine agents, the anti-IL12/IL23 monoclonal a Read More
-
-
-
JAK Inhibition: The Most Promising Agents in the IBD Pipeline?
Authors: Agnès Fernández-Clotet, Jesús Castro-Poceiro and Julián PanésUnder current therapeutic algorithms, half of the patients with moderate-severe ulcerative colitis or Crohn’s disease fail in achieving a sustained remission. New drugs with different mechanisms of action are needed. After two decades of new drug avenues in inflammatory bowel disease dominated by the development of monoclonal antibodies, in recent years we are witnessing promising developments of small molecules Read More
-
-
-
Cell-based Therapy for Perianal Fistulising Crohn’s Disease
Authors: Paulo G. Kotze, Antonino Spinelli and Amy Lee LightnerBackground: The management of complex perianal fistulas in Crohn’s disease (CD) represents a challenge for patients, gastroenterologists and colorectal surgeons. There are clear limitations with current medical and surgical options, and healing rates remain far from what is expected. A multidisciplinary approach with optimized medical therapy, usually anti-TNF agents, associated with setons and additional surgical techni Read More
-
-
-
Anti-fibrotic Drugs for Crohn’s Disease: Ready for Prime Time?
Intestinal fibrosis, driven by chronic inflammation in Crohn’s disease, can be defined as an excessive accumulation of extracellular matrix in the affected gut segment ultimately leading to an impaired wound healing and cumulative tissue damage, possibly resulting in organ dysfunction, formation of stenotic lesions and necessity of surgical intervention. Despite continuous advances in developing novel treatment modaliti Read More
-
-
-
Novel Targets For Therapeutic Intervention in Inflammatory Bowel Disease. What is the Best Way to Assess the Safety Profile of a Drug?
Authors: Clara Yzet, Stacy S. Tse, Maia Kayal, Robert Hirten and Jean-Frédéric ColombelThe emergence of biologic therapies has revolutionized the management of inflammatory bowel disease (IBD) by halting disease progression, increasing remission rates and improving long-term clinical outcomes. Despite these well-described benefits, many patients are reluctant to commence therapy due to drug safety concerns. Adverse events can be detected at each stage of drug development and during the po Read More
-
-
-
Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials?
Authors: Christopher R. Lindholm and Corey A. SiegelInflammatory bowel disease (IBD) is a chronic inflammatory disease characterized by periodic episodes of flares and remission. Treatment is aimed at healing the bowel, to ultimately decrease hospitalization rates, need for surgeries and overall disability. In more recent years, treatment has transitioned from a reactive approach to a more proactive approach focusing on treating disease earlier and preventing complications. Read More
-
-
-
Particularities of IBD Trials in Children
By Dan TurnerPediatric inflammatory bowel diseases (IBD) are similar to the adult-onset type in many aspects, including the necessity of high-quality randomized controlled trials. However, recruiting children into clinical trials is conceptually more challenging than in adults. Furthermore, the long delay between adult and pediatric approval of new drugs leads not only to the unbearable extensive use of these drugs as off-label without ap Read More
-
-
-
Testosterone Replacement Therapy Has Limited Effect on Increasing Bone Mass Density in Older Men: a Meta-analysis
Authors: Wang Junjie, Hao Dongsheng, Sun Lei, Li Hongzhuo and Sun ChangyingBackground: Testosterone insufficiency may play a role in age-related decreases in bone mass density (BMD) and osteoporosis in aging men. Testosterone replacement therapy (T therapy) seems to be a simple and convenient way to increase BMD and improve the condition of osteoporosis. Objective: To evaluate the effects of T therapy in increasing BMD among older men with low serum testosterone concentr Read More
-
-
-
Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias
Authors: Michele Scognamiglio, Dario Costa, Antonio Sorriento and Claudio NapoliCoronary heart disease (CHD) remains the leading cause of disability and death in industrialized Countries. Among many conditions, which contribute to the etiology and progression of CHD, the presence of high low density lipoprotein-cholesterol (LDL-C) levels represents the major risk factor. Therefore, the reduction of LDL-C levels plays a key role in the management of patients with high or very high cardiovascular risk Read More
-
-
-
A Uniquely Modified DKL-based Peptide Probe for Positron Emission Tomography Imaging
Authors: Yi Liu, Zhengjie Wang, Xiang Li, Fei Kang, Xiaowei Ma, Weidong Yang, Wenhui Ma and Jing WangPeptides containing the asparagine-glycine-arginine (NGR) motif can target the tumor neovascular biomarker CD13/aminopeptidase N receptor. D-K6L9 is a tumor-selective anti-cancer peptide. To improve the capacity of NGR peptides to target tumors, we joined the NGR and D-K6L9 peptides to form NKL. Next, we linked 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to NKL and labeled it with gallium 68 (68Ga, Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
- Issue 46
- Issue 45
- Issue 44
- Issue 43
- Issue 42
- Issue 41
- Issue 40
- Issue 39
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
